Skip to content
You can now search across every topic, entity and event.What's new
Pandemics and Biosecurity
21JUL

FAO costs drug-resistance inaction at $318bn

2 min read
09:12UTC

The FAO put a price on antimicrobial resistance on 3 June, projecting $318bn in cumulative livestock losses by 2040, about six times the cost of acting now.

ScienceDeveloping
Key takeaway

Pricing drug resistance as $318bn in lost production reaches ministries a death toll never moved.

The Food and Agriculture Organization (FAO), the UN's Rome-based agency for food and farming, put a price on inaction over AMR (antimicrobial resistance, the process by which bacteria stop responding to the drugs meant to kill them) on 3 June. Its report projects global antimicrobial use in livestock rising 30% by 2040 against a 2019 baseline, and cumulative livestock production losses reaching $318bn by 2040 under a high-resistance scenario 1. That $318bn runs about six times the cost of acting now.

May's adoption of the WHO Global Action Plan on AMR set a mortality target, a 10% cut in bacterial AMR deaths by 2030. FAO has now attached a balance-sheet figure to the alternative, routing the same problem through food-security economics to reach an audience that a death toll did not. The 6:1 inaction-to-action ratio is the lever, reframing mitigation spending as loss avoidance rather than public-health cost.

Cheap antibiotics keep crowded herds productive, so use climbs with demand for meat, and resistance follows the use, an unremarkable chain that the $318bn figure now prices. Pricing the loss in production rather than deaths is how the issue reaches the agriculture and finance ministries that control the antibiotics and that a public-health framing never reached.

Deep Analysis

In plain English

Farmers use antibiotics to keep livestock healthy and speed up animal growth. When antibiotics are used too frequently, bacteria evolve to resist them, making those drugs less effective for both animals and humans over time. This is called antimicrobial resistance, or AMR. FAO, the UN's food and agriculture body, published a report on 3 June estimating that unchecked AMR will cost the farming industry $318 billion in lost livestock production by 2040, as animals die from infections that should be treatable. Preventing that outcome would cost around one-sixth as much. The report argues that tackling antibiotic overuse in farming serves both economic and public health goals.

Deep Analysis
Root Causes

The projected 30% rise in livestock antimicrobial use to 2040 reflects a structural dependency: antibiotic prophylaxis compensates for suboptimal biosecurity in intensive production systems. The economic incentive structure rewards volume and speed of production over herd health investment, particularly in markets where veterinary drug regulation is weak or enforcement is absent.

The WHO GAP-AMR 2026-2036, adopted 23 May, sets a 10% reduction target in AMR-attributable deaths by 2030 , a human-health metric. The FAO report reframes AMR as a food-security and economic threat independent of that metric, addressing a different political constituency: agriculture ministries and development finance institutions that do not engage with WHO's public-health framing.

What could happen next?
  • Consequence

    FAO's $318bn figure provides an economic mandate for agriculture ministries to engage with the WHO GAP-AMR 2026-2036 (ID:3599) framework , translating a public-health target into a production-economics argument that reaches beyond health ministry budgets.

  • Risk

    The 30% projected rise in livestock antimicrobial use by 2040 is concentrated in regions with limited veterinary drug regulatory capacity, meaning the economic cost will fall disproportionately on small-scale farmers in lower-income countries who have the least ability to absorb it.

Sources:FAO
First Reported In

Update #6 · Ebola outbreak gets an R0, and a fork

FAO· 9 Jun 2026
Read original
Different Perspectives
UK Government
UK Government
The Biological Security Strategy implementation report published 14 July commits the UK to deciding within twelve months whether to make DNA-synthesis screening mandatory, backed by GBP 1.83bn for biosecurity centres. It is a preemptive move on a threat that has not yet produced a UK incident.
Cambodia's Ministry of Health
Cambodia's Ministry of Health
Cambodia confirmed a nine-month-old girl in Phnom Penh as its fourth 2026 H5N1 case on 11 July, the country supplying four of the world's seven new human cases since February. The ministry's confirmed-case cadence is running well ahead of a US surveillance system that has recorded nothing new since March.
Knowledge Ecology International
Knowledge Ecology International
KEI published proposed annex text on the day IGWG7 opened that would attach benefit-sharing duties to a product's market registration, regardless of whether the manufacturer used shared samples or only downloaded sequence data. It is the Africa Group's fallback position if the sample-based bargain fails to bind.
European Union
European Union
The EU and other industrialised states backed a hybrid model built on centralised infrastructure with more flexible access terms, the opposite design choice from the Africa Group's. Brussels wants conditions handled contractually once samples reach shared facilities, not attached to national custody of the material itself.
Africa Group / Algeria
Africa Group / Algeria
Algeria, speaking for the Africa Group at IGWG7, backed distributed national and regional laboratories under binding access conditions, arguing that supplying states must keep legal control of samples rather than surrender them into shared infrastructure.
Uganda's Ministry of Health
Uganda's Ministry of Health
Uganda discharged its last confirmed patient on 16 July and opened a 42-day countdown to declaring its own outbreak over, closing at 20 cases and 2 deaths with no new case since 21 June. This is a closing chapter running alongside DR Congo's still-worsening one, contingent on a border DRC can no longer see across.